公开(公告)号：US20240182858A1

公开(公告)日：2024-06-06

申请号：US18282450

申请日：2022-03-16

申请人： Astellas Pharma Inc. ,  Osaka University

发明人： Kenichiro SHIMATANI ,  Hiromu SATO ,  Masao SASAI ,  Yoshiki SAWA ,  Atsuhiro SAITO ,  Shigeru MIYAGAWA

IPC分类号： C12N5/077 ,  A61K35/44 ,  A61P7/00 ,  C07K14/50 ,  C12N5/10

CPC分类号： C12N5/0661 ,  A61K35/44 ,  A61P7/00 ,  C07K14/503 ,  C12N5/10

摘要： An object of the present invention is to provide a cell therapy that is expected to be useful as an angiogenic therapy for a peripheral vascular disease such as critical lower limb ischemia. Specifically, the object is to provide a pericyte having high angiogenic potential and a method for producing the same. A pericyte introduced a bFGF gene and a method for producing the same are provided.

公开(公告)号：US20240316115A1

公开(公告)日：2024-09-26

申请号：US18579093

申请日：2022-07-14

申请人： Astellas Pharma Inc. ,  OSAKA UNIVERSITY

发明人： Kenichiro SHIMATANI ,  Hiromu SATO ,  Masao SASAI ,  Yoshiki SAWA ,  Atsuhiro SAITO ,  Shigeru MIYAGAWA

IPC分类号： A61K35/44 ,  C12N5/071

CPC分类号： A61K35/44 ,  C12N5/069 ,  C12N2500/32 ,  C12N2500/90 ,  C12N2501/115 ,  C12N2501/135 ,  C12N2506/02 ,  C12N2509/00 ,  C12N2513/00 ,  C12N2533/52 ,  C12N2533/54

摘要： An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(−) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.

公开(公告)号：US20240335480A1

公开(公告)日：2024-10-10

申请号：US18579100

申请日：2022-07-14

申请人： Astellas Pharma Inc. ,  OSAKA UNIVERSITY ,  National Center for Child Health and Development

发明人： Kenichiro SHIMATANI ,  Hiromu SATO ,  Masao SASAI ,  Yoshiki SAWA ,  Atsuhiro SAITO ,  Shigeru MIYAGAWA

IPC分类号： A61K35/545 ,  A61K35/44 ,  C12N5/071

CPC分类号： A61K35/545 ,  A61K35/44 ,  C12N5/069 ,  C12N2506/02 ,  C12N2513/00

摘要： An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(−) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.

公开(公告)号：US20160046720A1

公开(公告)日：2016-02-18

申请号：US14927007

申请日：2015-10-29

申请人： Astellas Pharma Inc.

发明人： Hiromu SATO ,  Daisuke Yamajuku ,  Kazunori Arai ,  Mako Ogino

IPC分类号： C07K16/28

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K14/715 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C12P21/02

摘要： [Problem] To provide an anti-human TSLP receptor antibody that specifically binds to human TSLP receptor and inhibits an action of human TSLP through human TSLP receptor.[Means for Solution] An anti-human TSLP receptor antibody had been studied by the present inventors, and an anti-human TSLP receptor antibody comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3 was provided. It was revealed that the anti-human TSLP receptor antibody inhibits expression of TARC mRNA induced by TSLP and production of MDC proteins, and suppressed an allergic reaction in a monkey Ascaris antigen sensitization model, and then the present invention was completed.

摘要翻译： [问题]提供与人TSLP受体特异性结合并通过人TSLP受体抑制人TSLP的作用的抗人TSLP受体抗体。 [解决方案]本发明人研究了抗人TSLP受体抗体，抗人TSLP受体抗体包含由SEQ ID NO：1的氨基酸序列1〜118的氨基酸序列构成的重链可变区 提供由SEQ ID NO：3的氨基酸序列号1至108组成的轻链可变区。 显示抗人TSLP受体抗体抑制由TSLP诱导的TARC mRNA的表达和MDC蛋白的产生，并抑制猴蛔虫抗原致敏模型中的过敏反应，然后完成本发明。

公开(公告)号：US20160208005A1

公开(公告)日：2016-07-21

申请号：US15090051

申请日：2016-04-04

申请人： Astellas Pharma Inc.

发明人： Hiromu SATO ,  Daisuke Yamajuku ,  Kazunori Arai ,  Mako Ogino

IPC分类号： C07K16/28

CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K14/715 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  C12P21/02

摘要： An anti-human TSLP receptor antibody that specifically binds to human TSLP receptor and inhibits an action of human TSLP through human TSLP receptor. A method for preventing or treating asthma by administering the anti-human TSLP receptor antibody or an antigen-binding fragment thereof. An anti-human TSLP receptor antibody had been studied by the present inventors, and an anti-human TSLP receptor antibody including a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3 was provided. It was revealed that the anti-human TSLP receptor antibody inhibits expression of TARC mRNA induced by TSLP and production of MDC proteins, and suppressed an allergic reaction in a monkey Ascaris antigen sensitization model.

摘要翻译： 特异性结合人TSLP受体并通过人TSLP受体抑制人TSLP的作用的抗人TSLP受体抗体。 通过施用抗人TSLP受体抗体或其抗原结合片段来预防或治疗哮喘的方法。 本发明人研究了抗人TSLP受体抗体，包含由SEQ ID NO：1的氨基酸序列1〜118的氨基酸序列构成的重链可变区的抗人TSLP受体抗体和 提供了由SEQ ID NO：3的氨基酸编号1至108的氨基酸序列组成的轻链可变区。 显示抗人TSLP受体抗体抑制由TSLP诱导的TARC mRNA的表达和MDC蛋白的产生，并抑制猴蛔虫抗原致敏模型中的过敏反应。